Compare DexCom, Inc. (DXCM) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Intuitive Surgical, Inc. — how do they compare? DexCom, Inc. trades at $77.81 (market cap $28.06B), while Intuitive Surgical, Inc. trades at $401.89 (market cap $137.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 4.9× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | ISRG | |
|---|---|---|
Market Cap | $28.06B | $137.76B |
Sector | Health | Health |
52-Week High | $89.53 | $592.85 |
52-Week Low | $54.84 | $379.50 |
Enterprise Value | $27.03B | $133.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Intuitive Surgical (ISRG) trades at $379.50, down 6.78% amid broader market pressure, yet maintains strong fundamentals with 28.15% net margins and consistent earnings beats. The stock faces technical headwinds with bearish moving averages but shows oversold RSI conditions. Recent news highlights competitive pressures but also strong da Vinci 5 adoption and upcoming Q2 earnings on July 16, where analysts expect another beat. Revenue growth remains robust at $10.06B for 2025, up from $8.4B in 2024.
Despite near-term volatility, ISRG's leadership in robotic surgery and analyst consensus price target of $552.36 suggest significant upside. Key risks include intensifying global competition and margin pressures, but the company's innovation pipeline and expanding procedure volumes support long-term growth. Institutional sentiment remains positive with 69.6% buy ratings, positioning ISRG as a compelling recovery candidate post-earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
